|
ALT | Altimmune, Inc. |
|
|
ALT | Altimmune, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 4.58 |
| Leverage | 18.06% |
| Market Cap | $ 160.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -90.8m |
| Margin | 28283.59% |
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.